![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 6 of 6. This is the beginning of the thread.
Posted by Hugh on December 1, 2020, at 12:41:44
A commonly used drug called fluvoxamine was recently tested as a treatment for COVID-19 in the United States. The 152 patients enrolled in the trial had been confirmed to have COVID-19 using a PCR test, and had seen symptoms appear within the past seven days.
Patients who already required COVID-19 hospitalisation, or who had an underlying lung condition, congestive heart failure or other immune conditions, were excluded. The study looked only at those who at the time had a relatively mild form of the disease.
Among these patients, the study found that taking fluvoxamine reduced the incidence of developing a serious COVID-19 condition over a 15-day period. None of the 80 patients treated with fluvoxamine deteriorated, whereas six (8.3%) of the 72 patients given a placebo saw their condition get worse. Their symptoms included shortness of breath, pneumonia and reduced blood oxygen.
The second week of COVID-19 infection is when clinical deterioration is normally seen--which suggests fluvoxamine could be a useful tool in stopping mild COVID-19 from getting worse.
Despite their name (selective serotonin reuptake inhibitors), some of these drugs are not entirely selective. In fact, fluvoxamine also binds to another brain cell protein called the σ-1 receptor (S1R). Fluvoxamine potently activates this protein, which has various functions, including inhibition of the production of cytokines - small signalling molecules that help direct the actions of immune cells. Cytokines are one of the most important chemical mediators of the immune response.
Thus, it is likely that the effect seen with fluvoxamine in COVID-19 patients has nothing to do with serotonin but everything to do with inhibiting the inflammatory response through the S1R. We know from studies in mice that fluvoxamine can decrease a sepsis-induced inflammatory response and the toxicity that comes with it.
It's worth noting that the research does have some limitations. These include a relatively small sample size and the fact that the most seriously affected COVID-19 patients were excluded from the study--we don't know whether it can help control the illness of severely afflicted patients. Certainly, the results need to be tested in a larger sample size over a longer period.
Nevertheless, in the race to find treatments to prevent and treat coronavirus infections, fluvoxamine could be a useful addition. If given during the initial fever and coughing phase of COVID-19, the drug could reduce the number of patients who develop the dangerous second phase of COVID-19, characterised by the cytokine storm and subsequent lung damage.
Given that the drug's therapeutic effects in COVID-19 may be mediated via the S1R, it would certainly be worth testing other S1R activators in COVID-19 patients. There are a variety of S1R activators already in clinical use. These include donepezil (used in Alzheimer's disease), citalopram, opipramol and amitriptyline (all used in depression and anxiety), dextromethorphan (used for coughs and colds) and pentazocine (used for pain relief).
Other anti-inflammatory drugs, such as colchicine and corticosteroids, have already been tested in COVID-19 patients with some positive effects. The potential repurposing of already approved drugs, especially cheap and orally active drugs like fluvoxamine, which we know to be safe, could speed up getting treatments to COVID-19 patients.
Complete article:
https://medicalxpress.com/news/2020-11-antidepressant-covid-.html
Posted by Phillipa on December 1, 2020, at 17:48:28
In reply to Antidepressant could treat COVID-19, posted by Hugh on December 1, 2020, at 12:41:44
Hugh I also read an article on Luvox been taking tiny doses of it for years. The study I read stated the dosing was 300 mg per day given in divided doses of l00mg a piece. But if the starting dose of luvox is 50mg a day how can someone take 300mg a day without possible severe side effects? Phillipa
Posted by rjlockhart37 on December 1, 2020, at 18:25:35
In reply to Re: Antidepressant could treat COVID-19 » Hugh, posted by Phillipa on December 1, 2020, at 17:48:28
wished it was prozac instead of luvox to treat covid
Posted by undopaminergic on December 2, 2020, at 6:03:23
In reply to Antidepressant could treat COVID-19, posted by Hugh on December 1, 2020, at 12:41:44
There was already another thread on this topic:
https://www.dr-bob.org/babble/20201025/msgs/1112523.html-undopaminergic
Posted by rjlockhart37 on December 3, 2020, at 21:47:52
In reply to Re: Antidepressant could treat COVID-19, posted by undopaminergic on December 2, 2020, at 6:03:23
US pfizer has a vacinne on the way, there delivering fast to texas
hope it goes to other places fast too, but i've been reading abour anti-vaxxers saying
Posted by rjlockhart37 on December 3, 2020, at 21:50:38
In reply to Re: Antidepressant could treat COVID-19, posted by rjlockhart37 on December 3, 2020, at 21:47:52
covid seems to hit people who are travelling more, and boasting that there not gonna get it...like karma kicks in and they get it
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.